共 176 条
[1]
Butte M(2007)Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 111-22
[2]
Keir M(2018)Fundamental mechanisms of Immune Checkpoint Blockade Therapy Cancer Discov 8 1069-86
[3]
Phamduy T(1992)Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 3887-95
[4]
Sharpe A(2014)Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 563-7
[5]
Freeman G(2019)Immune checkpoint inhibitors of PD-L1 as cancer therapeutics J Hematol Oncol 12 92-43
[6]
Wei S(2021)PD-L1 immunohistochemistry assay comparison in Atezolizumab plus nab-paclitaxel-treated Advanced Triple-negative Breast Cancer JNCI-Journal of the National Cancer Institute 113 1733-9
[7]
Duffy C(2020)Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative Breast cancer Annals of Oncology: Official Journal of the European Society for Medical Oncology 31 582-21
[8]
Allison J(2018)Atezolizumab and Nab-Paclitaxel in Advanced Triple-negative Breast Cancer N Engl J Med 379 2108-70
[9]
Ishida Y(2000)Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen Appl Immunohistochem Mol Morphology: AIMM 8 61-8
[10]
Agata Y(2004)Long-term preservation of antigenicity on tissue microarrays Lab Invest 84 1071-9